Drug intelligence / Profile preview

Staphylococcus albicans tablets

Development stage: Unknown
Lead developer: Shandong Provincial Qianfoshan Hospital
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
Administration: Oral

Overview

Staphylococcus albicans tablets is an investigational oral immunomodulatory biologic composed of inactivated bacterial cells, including *Staphylococcus albus*, *Moraxella catarrhalis* (formerly *Neisseria catarrhalis*), and *Bacillus subtilis*. Developed for the treatment of bronchiectasis, the drug functions as a bacterial vaccine designed to enhance both non-specific and specific immune responses within the respiratory mucosa. By modulating mucosal immunity, it aims to reduce airway mucus secretion and retention, thereby decreasing the frequency of acute exacerbations and the risk of hospitalization. The therapy is currently being evaluated in multicenter clinical trials in China, with Qianfoshan Hospital serving as the lead sponsor and Qilu Pharmaceutical as the manufacturer.

Other names: Staphylococcus and Neisseria Tablets

Beyond the preview

Go deeper on Staphylococcus albicans tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus albicans tablets.

Explore the full profile